AU2021310499A1 - Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) - Google Patents

Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) Download PDF

Info

Publication number
AU2021310499A1
AU2021310499A1 AU2021310499A AU2021310499A AU2021310499A1 AU 2021310499 A1 AU2021310499 A1 AU 2021310499A1 AU 2021310499 A AU2021310499 A AU 2021310499A AU 2021310499 A AU2021310499 A AU 2021310499A AU 2021310499 A1 AU2021310499 A1 AU 2021310499A1
Authority
AU
Australia
Prior art keywords
antibody
cell
cancer
muc1
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021310499A
Other languages
English (en)
Inventor
Surender Kharbanda
Donald W. Kufe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xyone Therapeutics Inc
Dana Farber Cancer Institute Inc
Original Assignee
Xyone Therapeutics Inc
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xyone Therapeutics Inc, Dana Farber Cancer Institute Inc filed Critical Xyone Therapeutics Inc
Publication of AU2021310499A1 publication Critical patent/AU2021310499A1/en
Assigned to DANA-FARBER CANCER INSTITUTE, INC., XYONE THERAPEUTICS, INC. reassignment DANA-FARBER CANCER INSTITUTE, INC. Request for Assignment Assignors: DANA-FARBER CANCER INSTITUTE, INC., GENUS ONCOLOGY, LLC.
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
AU2021310499A 2020-07-16 2021-07-15 Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) Pending AU2021310499A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052599P 2020-07-16 2020-07-16
US63/052,599 2020-07-16
PCT/US2021/070881 WO2022016190A1 (en) 2020-07-16 2021-07-15 Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)

Publications (1)

Publication Number Publication Date
AU2021310499A1 true AU2021310499A1 (en) 2023-03-09

Family

ID=79554266

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021310499A Pending AU2021310499A1 (en) 2020-07-16 2021-07-15 Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Country Status (11)

Country Link
US (1) US20230265208A1 (https=)
EP (1) EP4182354A4 (https=)
JP (1) JP2023534959A (https=)
KR (1) KR20230116767A (https=)
CN (1) CN117693530A (https=)
AU (1) AU2021310499A1 (https=)
BR (1) BR112023000728A2 (https=)
CA (1) CA3186181A1 (https=)
IL (1) IL299903A (https=)
MX (1) MX2023000784A (https=)
WO (1) WO2022016190A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
EP4676976A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 antibodies and methods of use
WO2025217515A2 (en) 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287195B1 (en) * 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
US20170204191A1 (en) * 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
US10059775B2 (en) * 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)

Also Published As

Publication number Publication date
BR112023000728A2 (pt) 2023-03-21
EP4182354A1 (en) 2023-05-24
WO2022016190A1 (en) 2022-01-20
EP4182354A4 (en) 2024-12-25
KR20230116767A (ko) 2023-08-04
CN117693530A (zh) 2024-03-12
JP2023534959A (ja) 2023-08-15
IL299903A (en) 2023-03-01
CA3186181A1 (en) 2022-01-20
MX2023000784A (es) 2023-04-18
US20230265208A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
US12466895B2 (en) Antibodies against the MUC1-c/extracellular domain (MUC1-C/ECD)
US10617773B2 (en) Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP2017505625A5 (https=)
KR20190140943A (ko) 항-cd33 항체 제제
JP7815099B2 (ja) ＥＧＦＲｖＩＩＩと結合するモノクローナル抗体およびその使用
TW202110891A (zh) 抗psgl-1組合物及其用於調節骨髓細胞發炎表型之方法及用途
US20230265208A1 (en) Antibodies against the muc1-c/extracellular domain (muc1-c/ecd)
CA3220049A1 (en) Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd)
US20230382982A1 (en) Mutations that drive vh4 antibody autoreactivity
HK40102189A (zh) 针对muc1-c/胞外结构域(muc1-c/ecd)的抗体
EA049727B1 (ru) Антитела против muc1-c/внеклеточного домена muc1-c (muc1-c/ecd)
US20250277015A1 (en) Human monoclonal antibodies to eastern equine encephalitis virus and uses therefor
US20250304659A1 (en) HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 1 (SARS-CoV-1)
WO2026064353A1 (en) Diagnostics and therapeutics targeting slc13a3
WO2022226060A1 (en) Antibody cocktail for treatment of ebolavirus infections
WO2023187407A1 (en) Human monoclonal antibodies binding to sars-cov-2 and methods of use thereof
WO2024015760A2 (en) Human monoclonal antibodies to omicron variant of severe acute respiratory syndrome coronavirus 2 (sars-cov- 2)

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: DANA-FARBER CANCER INSTITUTE, INC.

Free format text: FORMER APPLICANT(S): DANA-FARBER CANCER INSTITUTE, INC.; GENUS ONCOLOGY, LLC.

Owner name: XYONE THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): DANA-FARBER CANCER INSTITUTE, INC.; GENUS ONCOLOGY, LLC.